ALNYLAM PHARMACEUTICALS, INC. Funds and ETFs Alnylam Pharmaceuticals, Inc.
Equities
ALNY
US02043Q1076
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 150.5 USD | -0.59% |
|
-1.22% | -21.39% |
ETFs positioned on Alnylam Pharmaceuticals, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 206 M€ | -.--% | ||
| 0.04% | 1,166 M€ | +0.26% | ||
| 0.04% | 607 M€ | +0.05% | ||
| 0.04% | 0 M€ | +8.70% | - | |
| 0.04% | 23 M€ | -.--% | - | |
| 0.04% | 786 M€ | -.--% | ||
| 0.04% | 0 M€ | +18.97% | ||
| 0.04% | 0 M€ | +8.24% | - | |
| 0.03% | 0 M€ | +9.42% | ||
| 0.03% | 205 M€ | -.--% | ||
| 0.03% | 322 M€ | +13.88% | ||
| 0.03% | 29 M€ | -.--% | - | |
| 0.03% | 0 M€ | +5.79% | - | |
| 0.03% | 0 M€ | +5.63% | - | |
| 0.03% | 1,006 M€ | -.--% | ||
| 0.03% | 414 M€ | +11.90% | - | |
| 0.02% | 0 M€ | +3.63% | - | |
| 0.02% | 0 M€ | +3.50% | - | |
| 0.02% | 7 M€ | +0.11% | - | |
| 0.02% | 6 M€ | +3.89% | ||
| 0.01% | 0 M€ | +2.80% | - | |
| 0.01% | 0 M€ | +0.32% | - | |
| 0.01% | 0 M€ | +0.50% | - | |
| 0.01% | 2 M€ | +3.16% | - | |
| 0.00% | 0 M€ | +0.34% | - |
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Calendar
16/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
150.5
USD
Average target price
220.4
USD
Spread / Average Target
+46.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.39% | 19.03B | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B | |
| +20.18% | 11.72B |
- Stock Market
- Equities
- ALNY Stock
- Funds and ETFs Alnylam Pharmaceuticals, Inc.
